Empowered Funds LLC Boosts Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Empowered Funds LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,603 shares of the medical equipment provider’s stock after acquiring an additional 291 shares during the period. Empowered Funds LLC’s holdings in Hologic were worth $294,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Hologic during the second quarter worth about $25,000. Wolff Wiese Magana LLC acquired a new stake in Hologic during the 3rd quarter worth approximately $25,000. iA Global Asset Management Inc. purchased a new position in Hologic in the 1st quarter valued at approximately $37,000. Sunbelt Securities Inc. acquired a new position in shares of Hologic in the second quarter worth $37,000. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

NASDAQ HOLX opened at $79.73 on Tuesday. The company has a fifty day moving average of $80.38 and a two-hundred day moving average of $78.38. The company has a market capitalization of $18.52 billion, a PE ratio of 23.94, a P/E/G ratio of 2.49 and a beta of 0.98. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 EPS. As a group, analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HOLX shares. Raymond James lifted their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Evercore ISI lifted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. UBS Group lifted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.